Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Observer-Blind, Randomized Trial to Evaluate the Immunogenicity and Safety of PanBlok at Three Dose Levels Adjuvanted With a Stable Oil-in-Water Emulsion Compared With PanBlok Without Adjuvant in Healthy Adults Aged 18 to 49 Years

NCT01612000 is registered in ClinicalTrials.gov with Protein Sciences Corporation as lead sponsor.

NCT NCT01612000
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01612000 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Observer-Blind, Randomized Trial to Evaluate the Immunogenicity and Safety of PanBlok at Three Dose Levels Adjuvanted With a Stable Oil-in-Water Emulsion Compared With PanBlok Without Adjuvant in Healthy Adults Aged 18 to 49 Years
Lead sponsor
Protein Sciences Corporation
Phase
Phase 1/2
Overall status
Completed
Start date
May 31, 2012
Completion date
December 31, 2013
Enrollment
341 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

influenza